Tech Times of New York
SEE OTHER BRANDS

Hottest science and technology news from New York

Tech Times of New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times of New York.

Press releases published on June 20, 2025

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET1 radiochemistry solution based on 18F-aluminium fluoride (AlF …

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat …

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients

– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology …

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)

LOUISVILLE, Ky., June 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera Pharmaceuticals, LLC for QINLOCK® (ripretinib), which has been approved by the U.S. Food …

Jeffs’ Brands and Impact Acquisitions Receive Approval from TSX Venture Exchange for Fort Products’ Merger at a Valuation of up to Approximately $15 Million

Jeffs’ Brands and Impact Acquisitions Receive Approval from TSX Venture Exchange for Fort Products’ Merger at a Valuation of up to Approximately $15 Million

Tel Aviv, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that the TSX Venture Exchange (“TSXV”) has …

Fury Announces Closing of Financing

Fury Announces Closing of Financing

TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce that, further to its previous announcement (see news release dated June 5, 2025), it has closed a private …

Ellomay Capital Announces the Closing of the Investment by Clal Insurance in Ellomay Capital’s 198 MW Italian Solar Portfolio

Ellomay Capital Announces the Closing of the Investment by Clal Insurance in Ellomay Capital’s 198 MW Italian Solar Portfolio

Tel-Aviv, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and the USA, …

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trial European Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people …

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST           CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination …

Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

ORION OYJ LEHDISTÖTIEDOTE 20.6.2025 klo 13.30          Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa CHMP suosittaa myyntiluvan …

Hyperscale Data Subsidiary Bitnile.com Accepting $TRUMP Meme Coin in its Social Casino

Hyperscale Data Subsidiary Bitnile.com Accepting $TRUMP Meme Coin in its Social Casino

LAS VEGAS, June 20, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that the $TRUMP meme coin is now an accepted payment method on Bitnile.com, the …

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 Recommendation …

Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées

Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées

S’il est approuvé, Cabometyx® sera le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’administration ou …

MAIV Announces Strategic Investment and Advisory Partnership with Covey

MAIV Announces Strategic Investment and Advisory Partnership with Covey

BERLIN, June 20, 2025 (GLOBE NEWSWIRE) -- MAIV, the on-chain platform for private equity deals, is proud to announce a strategic investment and advisory partnership with Covey, a web3-native firm specializing in advisory, capital, development, and …

PAIRMiners baut globale Cloud-Mining-Dienste aus, da XRP- und DOGE-Investoren nach Stabilität suchen

PAIRMiners baut globale Cloud-Mining-Dienste aus, da XRP- und DOGE-Investoren nach Stabilität suchen

Die Plattform unterstützt automatische tägliche Auszahlungen und Mining in mehreren Währungen in über 180 Ländern Bild von PAIRMiner BERLIN, June 20, 2025 (GLOBE NEWSWIRE) -- Angesichts der anhaltenden Volatilität auf dem Kryptomarkt wenden sich Anleger, …

VdoCipher Blocks Over 250,000 Video Piracy Attempts in Just 12 Months with New Detection Engine

VdoCipher Blocks Over 250,000 Video Piracy Attempts in Just 12 Months with New Detection Engine

GURUGRAM, India, June 20, 2025 (GLOBE NEWSWIRE) -- In a significant step toward securing online video content, VdoCipher has announced the success of its newly deployed Pirate Detection Engine, which has blocked over 250,000 piracy attempts in just the …

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced …

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting …

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo …

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse L’approbation est basée sur des résultats pivots montrant des améliorations de la rémission durable de la maladie et une …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service